PDCD1 and colorectal cancer: A combination of immune checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 antibodies, proved to be more effective than either regimen used separately for the combination of capecitabine/oxaliplatin with anti-PD-1 antibody in the MC38 colorectal cancer model.